BACKGROUND: Indices of body composition and muscular strength were compared between men with prostate cancer (PCa) treated with androgen deprivation therapy (ADT) and asymptomatic matched men.
METHODS: Nine subjects aged 63-83 years with PCa who received ADT (PCa+ADT; duration 6-180 months) and 11 asymptomatic aged-matched eugonadal men (HM) aged 59-80 years were assessed for prostate-specific antigen (PSA) and total testosterone (TT). Total body non-osseous lean mass (TBLM) and right thigh non-osseous fat-free mass (RTLM) were assessed using dual-energy X-ray absorptiometry. Peak torque of the right knee extensors at 0° s-1 (ISO) and 60° s-1 (CON), maximal handgrip strength of the dominant hand (MHS) and whole-body strength (WBS) were assessed. ISO and CON per unit mass of RTLM and MHS and WBS per unit mass of TBLM were calculated.
RESULTS: Age, height, mass, body mass index and prostate-specific antigen were comparable between groups (P>0·05), while TT was lower in PCa+ADT (P< 0·01). RTLM was similar between groups (P≥0·075). Absolute ISO and CON were lower for PCa+ADT (P< 0·01) as were CON per unit of RTLM and ISO per unit of RTLM (P< 0·05). Absolute MHS, WBS and MHS per unit of TBLM and WBS per unit of TBLM were lower for PCa+ADT (P< 0·01; P< 0·05).
CONCLUSIONS: Men with PCa who receive ADT experience significant losses in whole-body muscular strength compared with asymptomatic age-matched men, which may impair functional capacity. These losses in muscular strength appear to involve neuromuscular mechanisms that are yet to be identified.
Written by:
Girard D, Marino FE, Cannon J. Are you the author?
Exercise and Sports Science Laboratories, School of Human Movement Studies, Charles Sturt University, Bathurst, NSW, Australia.
Reference: Clin Physiol Funct Imaging. 2013 Sep 30. Epub ahead of print.
doi: 10.1111/cpf.12084
PubMed Abstract
PMID: 24119067
UroToday.com Prostate Cancer Section
